Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Surgical Oncology: Clinical Application of Translational Medicine
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Surgical Oncology: Clinical Application of Translational Medicine

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 20 August 2026 | Viewed by 2477

Special Issue Editor

Prof. Dr. Domenico Parmeggiani

E-Mail Website
Guest Editor
U.O.C. General Surgery and Oncological Physiopathology, University of Study of Campania “Luigi Vanvitelli”, 80138 Naples, Italy
Interests: endocrine surgery; thyroid surgery; minimally invasive surgery; nodule thermal ablation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Translational medicine translates basic research into useful tools to improve the knowledge and treatment of the pathogenesis of human cancer diseases. This Special Issue will explore advancements in molecular and clinical alterations in cancer and the evolving surgical oncology through research outcomes and innovative discoveries from both laboratory and clinical settings. Surgical oncology is rapidly evolving, bridging basic research and clinical applications to enhance cancer diagnosis, treatment, and patient outcomes.

Topics will include drug safety and the management of adverse events in oncology patients, as well as the emerging role of extracellular vesicles as biomarkers and therapeutic carriers. Additionally, the issue will cover the development of nanoparticles and nanomedicine for tumor targeting, drug delivery, and improved surgical outcomes.

The goal of this Special Issue is to gather original research and review articles that highlight the clinical applications of translational medicine in surgical oncology, fostering a multidisciplinary dialog among researchers, clinicians, and industry innovators.

Prof. Dr. Domenico Parmeggiani
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • surgical oncology
  • drug safety
  • adverse events
  • nanovesicles
  • targeted drug delivery
  • cancer biomarkers
  • precision oncology
  • tumor microenvironment
  • nanomedicine
  • personalized medicine
  • diagnostics
  • prognosis
  • innovative therapies
  • translational research

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

16 pages, 1109 KB  
Article
Monocyte-Driven Systemic Biomarkers and Survival After Pulmonary Metastasectomy in Metachronous Lung-Limited Oligometastatic Disease: A Retrospective Single-Center Study
by Hacer Boztepe Yesilcay, Asim Armagan Aydin, Ahmet Unlu, Sencan Akdag, Kamuran Yuceer and Mustafa Yildiz
J. Clin. Med. 2026, 15(2), 476; https://doi.org/10.3390/jcm15020476 - 7 Jan 2026
Viewed by 614
Abstract
Background/Objectives: Metachronous lung-limited oligometastatic disease represents a biologically heterogeneous state in which patient selection for pulmonary metastasectomy remains challenging. While systemic inflammation–nutrition indices have shown prognostic value across malignancies, their relevance in this strictly defined surgical setting is not well established. Methods: We [...] Read more.
Background/Objectives: Metachronous lung-limited oligometastatic disease represents a biologically heterogeneous state in which patient selection for pulmonary metastasectomy remains challenging. While systemic inflammation–nutrition indices have shown prognostic value across malignancies, their relevance in this strictly defined surgical setting is not well established. Methods: We conducted a retrospective single-center cohort study including 109 patients with isolated metachronous pulmonary recurrence who underwent curative intent R0 metastasectomy between September 2015 and April 2024. Preoperative systemic biomarkers, including neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), pan-immune-inflammation value (PIV), and monocyte-to-albumin ratio (MAR), were evaluated using receiver operating characteristic (ROC) analysis and multivariable Cox models to determine their association with overall survival (OS) and progression-free survival (PFS). Clinicopathological variables, such as lymph node involvement and metastatic burden, were incorporated into the adjusted models. Results: The median age of the cohort was 61 years (range, 29–82 years), and the sex distribution was balanced (48.6% female and 51.4% male), with 62.4% of patients being younger than 65 years. Among the systemic indices evaluated, monocyte-weighted biomarkers demonstrated the strongest prognostic performance. The MAR showed the highest discriminative ability for mortality (AUC, 0.749; p < 0.001), followed by the SIRI (AUC, 0.682; p = 0.007). In multivariable analyses, MAR independently predicted OS (p = 0.043) and PFS (p = 0.023), while SIRI independently predicted PFS (p = 0.043). Lymph node involvement remained the dominant adverse prognostic factor for both outcomes (p < 0.001); however, monocyte-weighted indices provided additional prognostic value beyond conventional anatomic criteria. Conclusions: Preoperative SIRI and MAR capture host immune–metabolic states that are relevant to postoperative trajectories and may refine risk stratification in candidates for pulmonary metastasectomy. These readily obtainable markers warrant prospective validation within biologically integrated selection frameworks. Full article
(This article belongs to the Special Issue Surgical Oncology: Clinical Application of Translational Medicine)
►▼ Show Figures

Figure 1

Review

Jump to: Research

16 pages, 309 KB  
Review
Nanoparticles in Thyroid Autoimmunity: Diagnostic and Therapeutic Applications
by Giusy Elia, Silvia Martina Ferrari, Francesca Ragusa, Eugenia Balestri, Chiara Botrini, Federica Colapietra, Paola Della Monica, Alessandro Antonelli, Poupak Fallahi and Marina Di Domenico
J. Clin. Med. 2026, 15(4), 1428; https://doi.org/10.3390/jcm15041428 - 12 Feb 2026
Viewed by 560
Abstract
Autoimmune thyroid diseases (AITDs) represent T cell-mediated, organ-specific autoimmune disorders caused by immune dysregulation, culminating in an immune-mediated attack on thyroid tissue. AITD etiopathogenesis is the result of the interplay between a genetic susceptibility and environmental factors; hypothyroidism and thyrotoxicosis are the respective [...] Read more.
Autoimmune thyroid diseases (AITDs) represent T cell-mediated, organ-specific autoimmune disorders caused by immune dysregulation, culminating in an immune-mediated attack on thyroid tissue. AITD etiopathogenesis is the result of the interplay between a genetic susceptibility and environmental factors; hypothyroidism and thyrotoxicosis are the respective clinical hallmarks of autoimmune thyroiditis and Graves’disease, the two main forms of AITD. The application of nanomedicine in the context of thyroid disorders ranges from nanodiagnosis and nanotherapy to nanotheranostics. Nanomedicine has been used to develop new sensitive methods for the determination of the TSH, iodine and TSAb. Furthermore, other studies have used nanomedicine to explore new treatments of autoimmune thyroiditis, Graves’disease and also thyroid eye disease. In the future, the application of nanomedicine will be personalized in accordance with individual genetic profiles, thus improving the therapeutic effectiveness and reducing the undesirable side effects with improved patient outcomes. Full article
(This article belongs to the Special Issue Surgical Oncology: Clinical Application of Translational Medicine)
15 pages, 1087 KB  
Review
Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature
by Raffaella Pagliaro, Paola Della Monica, Vito D’Agnano, Angela Schiattarella, Antonio D’Orologio, Paola Maria Medusa, Giulia Maria Stella, Federica Colapietra, Fabio Perrotta, Andrea Bianco, Marina Di Domenico and Filippo Scialò
J. Clin. Med. 2026, 15(3), 996; https://doi.org/10.3390/jcm15030996 - 26 Jan 2026
Cited by 1 | Viewed by 911
Abstract
The management of lung cancer (LC) in patients with interstitial lung diseases (ILDs) presents significant challenges, particularly with the increasing use of immunotherapy (IT). Immunotherapy-related pneumonitis (ICIP) is a potential complication of immune checkpoint inhibitors (ICIs) that can be difficult to differentiate from [...] Read more.
The management of lung cancer (LC) in patients with interstitial lung diseases (ILDs) presents significant challenges, particularly with the increasing use of immunotherapy (IT). Immunotherapy-related pneumonitis (ICIP) is a potential complication of immune checkpoint inhibitors (ICIs) that can be difficult to differentiate from pre-existing or treatment-induced ILD. The incidence of treatment-related pneumonitis is higher in patients with pre-existing ILD, which complicates the therapeutic approach. Moreover, antifibrotic drugs have shown potential in reducing the incidence of post-operative acute exacerbations in IPF patients undergoing surgery and radiotherapy. ILDs in LC patients can either develop ab initio, linked to environmental exposures, autoimmune diseases, or emerge because of cancer therapies. Although large-scale clinical trial evidence remains limited, careful therapy selection, early detection of pneumonitis, and close monitoring are crucial. Further prospective studies are needed to refine therapeutic strategies, particularly regarding the role of IT in this sensitive population and the role of combination therapies with antifibrotics and ICIs to optimize outcomes for patients with both LC and ILDs. This review summarizes the available evidence on the safety and efficacy of IT in this population, emphasizing the importance of personalized treatment approaches and vigilant monitoring. Full article
(This article belongs to the Special Issue Surgical Oncology: Clinical Application of Translational Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop